Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 51 - 86 av 86 resultater
Tid
Selskap
Tittel
Sektor
Kategori
01 Sep 2022
20:00 CEST
ONXEO
High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie
20103010 Biotechnology
Other subject
01 Sep 2022
20:00 CEST
ONXEO
Gliome de haut grade récidivant chez l’enfant : Onxeo annonce l’inclusion du 1er patient dans l’essai clinique de phase 1b/2 mené par le consortium européen ITCC, avec la promotion de l'Institut Curie
20103010 Biotechnology
Other subject
30 Aug 2022
20:05 CEST
ONXEO
Onxeo Announces That Nasdaq Approved the Delisting of Its Shares From the First North Growth Market in Copenhagen
20103010 Biotechnology
New
30 Aug 2022
20:05 CEST
ONXEO
Onxeo annonce l’approbation par le Nasdaq du retrait de ses actions de la cote du marché First North de Copenhague
20103010 Biotechnology
New
17 Aug 2022
20:00 CEST
ONXEO
Combined General Meeting of August 17, 2022: Onxeo Shareholders Approve Withdrawal From the Nasdaq First North Market in Copenhagen
20103010 Biotechnology
Other subject
17 Aug 2022
20:00 CEST
ONXEO
Les actionnaires d’Onxeo approuvent le retrait du marché Nasdaq First North de Copenhague
20103010 Biotechnology
Other subject
29 Jul 2022
18:46 CEST
ONXEO
Onxeo S.A.: Combined General Meeting of August 17, 2022: Availability of Preparatory Documents and Participation & Voting Procedures
20103010 Biotechnology
General meeting / Board Meeting
29 Jul 2022
18:46 CEST
ONXEO
Onxeo S.A. : Assemblée générale mixte le 17 août 2022 : mise à disposition des documents préparatoires et modalités de participation et de vote
20103010 Biotechnology
General meeting / Board Meeting
12 Jul 2022
19:03 CEST
ONXEO
Onxeo Announces a Combined General Meeting on August 17, 2022
20103010 Biotechnology
General meeting / Board Meeting
12 Jul 2022
19:03 CEST
ONXEO
Onxeo annonce la tenue d’une assemblée générale mixte le 17 août 2022
20103010 Biotechnology
General meeting / Board Meeting
04 Jul 2022
18:54 CEST
ONXEO
ONXEO : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC KEPLER CHEUVREUX
20103010 Biotechnology
Other subject
04 Jul 2022
18:54 CEST
ONXEO
Summary of ONXEO’s Liquidity Contract with Kepler Cheuvreux
20103010 Biotechnology
Other subject
30 Jun 2022
23:33 CEST
ONXEO
Onxeo : La demande initiale d’IND (Investigational New Drug) pour AsiDNA a reçu l’approbation « Study May Proceed » de la part de la FDA
20103010 Biotechnology
New
30 Jun 2022
23:33 CEST
ONXEO
Onxeo:Initial IND Application for AsiDNA Granted “Study May Proceed” by the U.S. FDA
20103010 Biotechnology
New
16 Jun 2022
07:30 CEST
ONXEO
Onxeo : compte rendu de l’assemblée générale mixte du 15 juin 2022
20103010 Biotechnology
General meeting / Board Meeting
16 Jun 2022
07:30 CEST
ONXEO
Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022
20103010 Biotechnology
General meeting / Board Meeting
28 Apr 2022
19:48 CEST
ONXEO
Onxeo: Publication of the 2021 Annual Financial Report
20103010 Biotechnology
Other subject
28 Apr 2022
19:48 CEST
ONXEO
Onxeo : Mise à disposition du rapport financier annuel 2021
20103010 Biotechnology
Other subject
07 Apr 2022
07:00 CEST
ONXEO
Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
20103010 Biotechnology
Journal / appointments
07 Apr 2022
07:00 CEST
ONXEO
Onxeo nomme le Dr Shefali Agarwal au poste de Présidente directrice générale
20103010 Biotechnology
Journal / appointments
06 Apr 2022
19:08 CEST
ONXEO
Onxeo Reports its Full-Year 2021 Financial Results and Announces Additional Financing of €12 Million
20103010 Biotechnology
Income
06 Apr 2022
19:08 CEST
ONXEO
Onxeo présente ses résultats financiers 2021 et annonce un nouveau financement de 12 millions d’euros
20103010 Biotechnology
Income
31 Mar 2022
18:43 CEST
ONXEO
Onxeo to Present New Preclinical Data Highlighting AsiDNA™’s Ability to Fight Tumor Resistance and Protect From Anticancer Treatment Toxicity at AACR Annual Meeting 2022
20103010 Biotechnology
New
31 Mar 2022
18:43 CEST
ONXEO
Onxeo présentera de nouvelles données précliniques mettant en évidence la capacité d'AsiDNA™ à lutter contre la résistance tumorale et à protéger de la toxicité des traitements anticancéreux lors du congrès annuel de l'AACR 2022
20103010 Biotechnology
New
09 Mar 2022
07:00 CET
ONXEO
Onxeo’s New Preclinical Data Confirm the Relevance of Combining AsiDNA™ With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors
20103010 Biotechnology
Other subject
09 Mar 2022
07:00 CET
ONXEO
De nouvelles données précliniques d'Onxeo confirment la pertinence de l’association d'AsiDNA™ avec des inhibiteurs de PARP dans le traitement des tumeurs avec une voie de recombinaison homologue active
20103010 Biotechnology
Other subject
13 Jan 2022
18:00 CET
ONXEO
Onxeo annonce son calendrier financier 2022
20103010 Biotechnology
Other subject
13 Jan 2022
18:00 CET
ONXEO
Onxeo Announces its Financial Agenda for 2022
20103010 Biotechnology
Other subject
07 Jan 2022
17:45 CET
ONXEO
ONXEO : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC KEPLER CHEUVREUX
20103010 Biotechnology
Other subject
07 Jan 2022
17:45 CET
ONXEO
Summary of Onxeo’s Liquidity Contract With Kepler Cheuvreux
20103010 Biotechnology
Other subject
03 Jan 2022
19:41 CET
ONXEO
Onxeo annonce la nomination de Julien Miara en tant que nouveau Directeur général par interim
20103010 Biotechnology
Other subject
03 Jan 2022
19:41 CET
ONXEO
Onxeo Appoints Julien Miara as New Interim CEO
20103010 Biotechnology
Other subject
08 Dec 2021
18:00 CET
ONXEO
Onxeo: New Preclinical Data Confirm the Ability of AsiDNA™ to Tackle the Drug-Tolerant Persister Cells and Prevent Tumor Resistance in Several Combination Treatments
20103010 Biotechnology
New
08 Dec 2021
18:00 CET
ONXEO
Onxeo : De nouvelles données précliniques confirment la capacité d'AsiDNA™ à cibler les cellules « persistantes » et prévenir la résistance tumorale liée à différents traitements en association
20103010 Biotechnology
New
23 Nov 2021
19:00 CET
ONXEO
Onxeo poursuit le renforcement de son conseil d'administration
20103010 Biotechnology
New
23 Nov 2021
19:00 CET
ONXEO
Onxeo Continues to Strengthen its Board of Directors
20103010 Biotechnology
New
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
1
2
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva